We initiate on Advanced Oncotherapy. The company has significant growth potential in the nascent but fast growing Proton therapy ("PT") industry. AVO's high quality industry partners like Thales facilitate industrialisation and quick ramp up. We expect 20% top line growth for the PT sector in 2016 and double digit in the mid term driven by a PT conversion rate of 15% by 2030. This could result in a c.$8.0bn market by 2030 including both machines and recurring services charges. AVO has a signi
31 Oct 2016
Advanced Oncotherapy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Advanced Oncotherapy
Advanced Oncotherapy Plc (AVO:LON) | 1.9 0 0.0% | Mkt Cap: 10.4m
- Published:
31 Oct 2016 -
Author:
Martin Brunninger -
Pages:
42
We initiate on Advanced Oncotherapy. The company has significant growth potential in the nascent but fast growing Proton therapy ("PT") industry. AVO's high quality industry partners like Thales facilitate industrialisation and quick ramp up. We expect 20% top line growth for the PT sector in 2016 and double digit in the mid term driven by a PT conversion rate of 15% by 2030. This could result in a c.$8.0bn market by 2030 including both machines and recurring services charges. AVO has a signi